Attributes 417% Revenue Growth to innovative Specialty Pharmacy programs and services designed to optimize clinical outcomes and quality of life for patients with complex chronic conditions or rare diseases
BERWYN, Pa.--(BUSINESS WIRE)--AscellaHealth, a global specialty pharmacy and healthcare solutions company, today announced it ranked 299 on the Deloitte Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies in North America, now in its 27th year. AscellaHealth grew 417% during this period.
AscellaHealth Ranked Number 299 Fastest-Growing Company in North America on the 2021 Deloitte Technology Fast 500™
AscellaHealth’s Dea Belazi, president and CEO, credits their innovative Specialty Pharmacy programs and services for the company’s 417% revenue growth. He said, "Our programs and services are designed to optimize clinical outcomes and quality of life for patients with complex chronic conditions or rare diseases. Our focus on all sectors of the Specialty Pharmacy industry, including payers, providers, life sciences and patients, as well as gene and cell therapies, positions AscellaHealth for accelerated growth as we continue to expand the scope and diversity of our customer base."
“Each year the Technology Fast 500 shines a light on leading innovators in technology and this year is no exception,” said Paul Silverglate, vice chair, Deloitte LLP and U.S. technology sector leader. “In the face of innumerable challenges resulting from the pandemic, the best and brightest were able to pivot, reinvent and transform and grow. We celebrate the winning organizations and especially the talented employees driving their success.”
“The pandemic has underscored the urgent need for tech solutions in a variety of areas across health care, fintech, energy tech, entertainment, to name a few, so reliance on innovators like the winners of the Technology Fast 500 is more important than ever,” said Christie Simons, partner, Deloitte & Touche LLP and industry leader for technology, media and telecommunications within Deloitte’s audit & assurance practice. “These companies are not only at the cutting edge, transforming the way we do business, but most importantly, recognize the strategic importance of ongoing innovation, especially in the ever-changing world of technology.”
AscellaHealth previously ranked among honorees for the 2021 Inc. Magazine’s 5000 for 2021; earned the merit-based Philadelphia100 Award for the second consecutive year among the fastest growing, private companies in the Philadelphia region; and Dea Belazi was among the top honorees at the Philadelphia Business Journal’s 2021 “Most Admired CEOs.”
About the 2021 Deloitte Technology Fast 500™ Now in its 27th year, the Deloitte Technology Fast 500 provides a ranking of the fastest-growing technology, media, telecommunications, life sciences, fintech, and energy tech companies — both public and private — in North America. Technology Fast 500 award winners are selected based on percentage fiscal year revenue growth from 2017 to 2020.
In order to be eligible for Technology Fast 500 recognition, companies must own proprietary intellectual property or technology that is sold to customers in products that contribute to a majority of the company’s operating revenues. Companies must have base-year operating revenues of at least US$50,000, and current-year operating revenues of at least US$5 million. Additionally, companies must be in business for a minimum of four years and be headquartered within North America.
About AscellaHealth LLC AscellaHealth is a global Specialty Pharmacy and Healthcare services organization serving payers, providers, life sciences and patients, offering a comprehensive portfolio of customized, tech-enabled specialty pharmaceutical and medical management services. An Inc. 5000 2021 winner, AscellaHealth’s unique, patient-centric approach is built upon proprietary technology processes for innovative programs and services optimizing health outcomes and quality of life for patients with complex chronic conditions or rare diseases that require specialty medications and/or gene and cell therapies. Visit www.AscellaHealth.com.
About Deloitte Deloitte refers to one or more of Deloitte Touche Tohmatsu Limited, a UK private company limited by guarantee (“DTTL”), its network of member firms, and their related entities. DTTL and each of its member firms are legally separate and independent entities. DTTL (also referred to as “Deloitte Global”) does not provide services to clients. In the United States, Deloitte refers to one or more of the US member firms of DTTL, their related entities that operate using the “Deloitte” name in the United States and their respective affiliates. Certain services may not be available to attest clients under the rules and regulations of public accounting. Please see www.deloitte.com/about to learn more about our global network of member firms.